Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. - Wikidata - wikimedia - TriplyDB

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

http://www.wikidata.org/entity/Q37154615

about

Important molecular genetic markers of colorectal cancer.KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.

P2860

Q37619856-D78DEB00-CB29-4858-996D-727C185101E4 Q39078976-622A0AC7-F59D-44E7-9D50-46B8FA16C1FB

P2860

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

http://www.wikidata.org/entity/Q37154615

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

@en

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

@nl

type

label

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

@en

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

@nl

prefLabel

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

@en

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

@nl

P1433

Q37154615-435F20C5-D41D-4E18-9B21-49EEECF43F8C

P1476

Q37154615-030FF947-957A-49D0-BBE5-327F039E5F03

P2093

Q37154615-4EA21E67-AD67-450A-AAA4-1DFEFBF2ED0C

Q37154615-5DE1EEC9-77CB-4FD3-912E-7AE4F3C40AF3

P2860

Q37154615-046979E0-1378-4BD5-B76C-6CF564704FEC

Q37154615-155DC1F9-59C0-4DDB-9412-209183FE2600

Q37154615-1FA9458D-C73A-4043-BABB-F3E10979CBE8

Q37154615-250A077F-E95E-405A-A9D2-7AED7D3B3043

Q37154615-2F168D59-8A76-474B-BBA0-42FE897ABA65

Q37154615-30780C6E-358B-406A-8E39-42E9D0DC0C1D

Q37154615-318E6565-2019-4A5C-B39A-414AD7AC6A56

Q37154615-380EA2E1-C11C-44D3-96BC-737FA0E4641E

Q37154615-3BCB083D-8887-4D03-8C46-0FA2F6950323

Q37154615-675FD426-65CF-472E-BF3D-1FBB1D31AD27

P2888

Q37154615-6A3298CE-4297-45EB-85C6-00461A362F52

P304

Q37154615-E1773ECD-B411-452E-A1A7-8A6A4688D7A7

P31

Q37154615-1885D5B6-C79C-46B7-8F65-BB74E8CE5D6A

P356

Q37154615-7808A6E3-60CE-4ECB-A4B1-EAA22E0635D4

P433

Q37154615-7E5D3F5F-32BD-4974-A0C4-520C374444C9

P478

Q37154615-5F3E4570-1A32-4F4B-927A-F98E3A119004

P50

Q37154615-05627700-C453-4C21-8CAF-67923937E62A

Q37154615-905AAAEB-6833-40C7-80B6-1ABB4E18336E

P577

Q37154615-0D522363-411E-400A-9DC5-EE447DACB801

P698

Q37154615-B27BA70A-CFF4-4BC7-AEB8-E36BBBC705D9

P921

Q37154615-1AF97434-C7CA-40E2-BB31-F381A7014C7B

Q37154615-F6F720EB-A833-4E25-8D13-F9A6AAA69264

P932

Q37154615-0B21EB35-0B6A-413A-8950-6BF7E9B28B9C

P356

S11523-013-0266-9

P1433

Targeted oncology

P1476

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

@en

P2093

David S Hong

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

P2860

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

BRAF mutation predicts sensitivity to MEK inhibition

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

P2888

s11523-013-0266-9

P304

183-188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-013-0266-9

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23400451

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3766504

http://www.w3.org/2001/XMLSchema#string